Name: 글로벌 시장 동향
SKU: PH6770
Availability: InStock

보고서 요약(국문)

개요
전 세계 동형접합성 가족성 고콜레스테롤혈증(HoFH) 시장은 2022년 8,370만 달러 규모에 도달했으며, 2023년부터 2030년까지 연평균 2.5%의 성장률을 보이며 2030년에는 1억 180만 달러에 이를 것으로 예상됩니다. HoFH를 유발하는 유전적 돌연변이를 정확하게 식별하여 조기 진단을 가능하게 하는 유전자 진단 기술의 발전과 같은 추세가 전 세계 HoFH 시장 성장을 주도할 것으로 전망됩니다.
전 세계 HoFH 시장은 최근 몇 년간 크게 성장했으며, 이러한 상승세는 지속될 것으로 예상됩니다. 이 시장은 CRISPR-Cas9 및 RNA 간섭(RNAi)과 같은 새로운 기술 개발 등 여러 중요한 추세의 영향을 받아 전환기를 맞고 있습니다.

또한, 심혈관 질환의 유병률 증가, 단클론 항체와 같은 잠재적 신흥 치료법의 출시, 질병에 대한 인식 제고, 임상 시험 건수 증가 등이 동형접합성 가족성 고콜레스테롤혈증 시장 규모 확대를 견인하고 있습니다.
동형접합성 가족성 고콜레스테롤혈증 접근법을 이용한 질병 치료 연구 활동 증가와 유력한 바이오제약 및 제약 회사의 존재는 북미 지역 수요 증가의 주요 요인입니다. 아스트라제네카, 비아트리스, 어코드 헬스케어 등 주요 경쟁 업체들이 시장에서 활발하게 활동하고 있습니다.
시장 동향
심혈관 질환 유병률 증가가 동형접합성 가족성 고콜레스테롤혈증 시장 성장을 견인할 전망
심혈관 질환(CVD)의 유병률 증가는 동형접합성 가족성 고콜레스테롤혈증(HoFH) 시장 성장의 주요 동인입니다. HoFH는 높은 LDL-C 수치와 심장마비, 뇌졸중과 같은 심혈관 질환 위험 증가를 특징으로 하며, 이 질환에 대한 인식이 높아짐에 따라 조기 발견 및 개입이 촉진되고 있으며, 이는 효과적인 HoFH 치료에 대한 수요를 증가시키고 있습니다.
예를 들어, 미국 질병통제예방센터(CDC)의 2023년 보고서에 따르면 심장 질환은 미국에서 주요 사망 원인 중 하나입니다. 미국에서는 40초마다 한 명씩 심장마비를 겪습니다. 매년 약 80만 5천 명이 심장마비를 경험합니다. 또한 관상동맥 질환은 가장 흔한 심장 질환 유형으로, 2021년에 37만 5476명의 사망자를 냈습니다. 심혈관 질환 및 관상동맥 질환의 부담이 계속 증가함에 따라 HoFH 시장은 예측 기간 동안 성장할 것으로 예상됩니다.

유전자 치료의 지속적인 발전이 동형접합성 가족성 고콜레스테롤혈증 시장 성장을 견인할 것입니다.
CRISPR-Cas9, 소형 간섭 RNA(siRNA), 엑소좀 매개 치료법 등 동형접합성 가족성 고콜레스테롤혈증 치료 분야에서 기술 발전이 가속화됨에 따라 시장 수요가 증가할 것으로 예상됩니다. CRISPR/Cas9 시스템은 ZFN 및 TALEN에 이어 3세대 유전자 편집 기술로, 현재 가장 선호되는 유전자 편집 도구입니다.
예를 들어, 미국 국립 의학 도서관(National Library of Medicine)의 2022년 논문에 따르면, CRISPR/Cas9 유전자 편집 시스템을 포함하는 아데노 관련 바이러스(AAV)(AAV-CRISPR/Cas9)가 최근 생체 내 동물 연구에서 LDL 수용체 기능이 손상된 LDLR 돌연변이 마우스를 표적으로 삼는 데 사용되었습니다. 연구진은 AAV-CRISPR/Cas9 유전자 편집 기술을 이용하여 간세포의 돌연변이를 부분적으로 교정하고 LDL 수용체 단백질 발현을 복원할 수 있음을 발견했습니다.
이로 인해 혈청 총 콜레스테롤, 중성지방, LDL 콜레스테롤 수치가 크게 감소했습니다. 결과적으로 대동맥의 죽상경화성 플라크 형성이 현저히 줄어들어 CRISPR/Cas9 기술이 이형접합성 및 동형접합성 가족성 고콜레스테롤혈증 치료에 대한 잠재력을 가지고 있음을 보여줍니다. 따라서 유전자 치료 기술의 발전은 예측 기간 동안 시장 수요를 견인할 것입니다.
하지만 동형접합성 가족성 고콜레스테롤혈증 치료의 높은 비용은 시장 성장을 저해할 수 있습니다.
동형접합성 가족성 고콜레스테롤혈증 치료의 높은 비용은 이 시장의 중요한 장벽입니다. 이러한 약물의 높은 가격은 환자들이 감당하기 어렵게 만들어 많은 사람들이 필수적인 치료를 받지 못하게 할 수 있습니다. 이러한 재정적 부담은 저소득 지역의 더 많은 사람들에게 영향을 미쳐, 동형접합성 가족성 고콜레스테롤혈증(HoFH) 환자의 생명을 구할 수 있는 치료를 받을 수 있는 기회에 격차를 초래할 수 있습니다.
예를 들어, 미국에서 Juxtapid라는 브랜드로 판매되는 저밀도 지질단백질(LDL) 제거제인 로미타피드(Lomitapide)는 약 5mg 캡슐 28정(28캡슐)에 약 53,471달러의 비용이 듭니다. 게다가, 제네릭 의약품의 부재로 인해 개발도상국 및 저소득 국가의 환자들은 이 약을 구입하는 데 어려움을 겪을 수 있습니다. 따라서, 위와 같은 요인들로 인해 시장은 가까운 미래에 제약을 받을 것으로 예상됩니다.
세분화 분석
전 세계 동형접합성 가족성 고콜레스테롤혈증 시장은 약물 종류, 투여 경로, 기술, 유통 채널 및 지역별로 세분화됩니다.

뛰어난 효능 덕분에 스타틴 부문은 동형접합성 가족성 고콜레스테롤혈증 시장 점유율의 약 47.6%를 차지했습니다.
스타틴 부문은 LDL 콜레스테롤 수치를 낮추고 심혈관 질환 위험을 관리하는 데 효과적이어서 동형접합성 가족성 고콜레스테롤혈증 시장을 주도할 것으로 예상됩니다. 스타틴은 3-하이드록시-3-메틸글루타릴 코엔자임-A(HMG-CoA) 환원효소에 작용하여 간의 콜레스테롤 합성을 억제함으로써 LDL-C를 낮추는 효능 때문에 동형접합성 가족성 고콜레스테롤혈증 치료의 주요 치료제로 사용되고 있습니다.
또한, 동맥경화증의 유병률 증가는 스타틴과 같은 치료법이 매우 효과적인 주요 요인입니다. 예를 들어, 가족 심장 재단(Family Heart Foundation)의 연구에 따르면 스타틴은 LDL 콜레스테롤을 35~55%까지 감소시킬 수 있으며, LDL 콜레스테롤이 40mg/dL 감소할 때마다 심혈관 질환 위험을 22% 줄일 수 있는 것으로 나타났습니다.
현재 로수바스타틴은 시판되는 스타틴 중 가장 강력한 지질 저하 효과를 가지고 있으며, 원발성 고지혈증, 혼합형 이상지질혈증, 동형접합성 가족성 고콜레스테롤혈증(FH), 원발성 이상베타지단백혈증, 고중성지방혈증 환자에게 권장됩니다. 또한 스타틴은 소아에게도 매우 효과적이며 지질 장애가 있는 소아에게 안전성이 입증되었습니다.
더욱이 스타틴은 에비나쿠맙, PCSK9 억제제 등 다른 보조 치료제와 병용 투여 시 효과가 더욱 높아집니다. 스타틴과 병용 투여되는 많은 신약들이 FDA 승인을 받을 것으로 예상됩니다. 따라서 스타틴의 우수한 효과로 인해 이 분야는 예측 기간 동안 시장을 주도할 것으로 전망됩니다.

지리적 시장 침투
북미는 동맥경화성 심혈관 질환(ASCVD) 유병률 증가에 힘입어 2022년 시장 점유율의 약 41.7%를 차지했습니다.
북미, 특히 미국은 이 지역에 주요 기업들이 다수 자리 잡고 있고, 동맥경화성 심혈관 질환(ASCVD) 유병률이 증가하고 있으며, 주요 기관들의 활발한 연구 활동과 기술 개발로 인해 전 세계 동형접합성 가족성 고콜레스테롤혈증 시장을 주도하고 있습니다.
예를 들어, 미국 국립 의학 도서관의 2022년 보고서에 따르면, 2019년 미국의 ASCVD 유병률은 약 2,400만 명에 달했으며, 이는 미국 전체 인구의 약 10%에 해당합니다. ASCVD 환자들은 동반 질환 부담이 높았으며, 31.2%는 재발 위험이 매우 높은 것으로 나타났습니다. 따라서 위와 같은 요인들로 인해 해당 지역은 예측 기간 동안 성장할 것으로 예상됩니다.
경쟁 환경
동형접합성 가족성 고콜레스테롤혈증 시장의 주요 글로벌 기업으로는 AstraZeneca, Viatris Inc., Teva Pharmaceutical Industries Ltd., Accord Healthcare, Changzhou Pharmaceutical Factory, Regeneron Pharmaceuticals, Inc., Amryt Pharma plc, Amgen Inc., Organon, Global Inc., CMP Pharma 등이 있습니다.
COVID-19 영향 분석
COVID-19 팬데믹은 가족성 고콜레스테롤혈증(FH) 환자, 특히 동형접합성 FH(HoFH) 환자의 생활 방식과 치료 관리에 상당한 영향을 미쳤습니다. COVID-19에 대한 공포로 인해 많은 사람들이 의료 서비스를 받지 않았습니다. 더욱이, FH 환자는 COVID-19 감염에 대한 취약성이 높아 고위험군으로 분류되었기 때문에 팬데믹 기간 동안 심혈관 질환 치료 및 예방에 대한 접근성이 제한되었습니다.

예를 들어, 2022년 미국 국립 의학 도서관 기사에 따르면, 이 인구 기반 연구에서는 코로나19에 감염된 가족성 고콜레스테롤혈증(FH) 환자의 급성 심근경색 위험이 상당히 증가하는 것으로 나타났습니다. 전반적으로, 코로나19 팬데믹은 FH 환자, 특히 동형접합성 가족성 고콜레스테롤혈증(HoFH) 환자의 심혈관 치료에 장애물을 만들었습니다. 이로써 동형접합성 가족성 고콜레스테롤혈증 시장에 큰 영향을 미쳤습니다.
약물 종류별
• 스타틴
• 콜레스테롤 흡수 억제제
• PCSK9 억제제
• MTP 억제제
• ANGPTL3 억제제
투여 경로별
• 경구
• 주사
• 비강 투여
기술별
• CRISPR-Cas9
• RNA 간섭
• 나노입자 기반 치료제
유통 채널별
• 병원
• 소매 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 동향
• 2023년 3월 22일, 리제네론 파마슈티컬스(Regeneron Pharmaceuticals, Inc.)는 FDA가 승인 기간을 연장했다고 발표했습니다. • 2021년 4월 1일, FDA는 동형접합성 가족성 고콜레스테롤혈증(HoFH)을 앓는 5~11세 소아 환자에게 다른 지질 저하제와 병용 투여하는 에브키자(에비나쿠맙-dgnb)의 사용을 승인했습니다. 에브키자는 HoFH로 인해 위험할 정도로 높은 저밀도 지질단백질 콜레스테롤(LDL-C) 수치를 낮추기 위해 5세 이상 소아에게 사용 승인된 최초의 안지오포이에틴 유사 3(ANGPTL3) 억제제입니다.
• 2021년 4월 1일, FDA는 콜레스테롤 수치를 현저히 높이는 유전 질환인 동형접합성 가족성 고콜레스테롤혈증(HoFH)을 앓는 성인 환자에게 주사제 프랄루엔트(알리로쿠맙)를 승인했습니다. 프랄루엔트는 단독 투여가 아닌 다른 HoFH 치료제와 병용 투여하는 약물입니다.

DMI 의견
유전자 진단, CRISPR-Cas9와 같은 유전자 치료법의 발전, 그리고 질환에 대한 인식 증가로 인해 전 세계 동형접합성 가족성 고콜레스테롤혈증(HoFH) 시장은 빠르게 성장할 것으로 예상됩니다. HoFH와 심혈관 질환의 연관성은 효과적인 치료법에 대한 수요를 창출하지만, 치료 비용 부담 능력과 접근성을 확보하는 것이 중요합니다. 유전자 편집 기술은 무궁무진한 가능성을 지니고 있지만, 문제점과 안전성 문제도 존재합니다.
시장은 여러 특성에 따라 세분화되어 있으며, 연구 역량과 질병 발생률 측면에서 북미 지역이 시장을 주도하고 있습니다. 에브키자(Evkeeza)와 프랄루엔트(Praluent)와 같은 새로운 치료법은 지속적인 혁신을 보여주고 있으며, 코로나19는 견고한 의료 시스템과 치료에 대한 공평한 접근성의 중요성을 강조했습니다. 이러한 환경 속에서 윤리적 문제와 발전 사이의 균형을 유지하는 것이 중요합니다.
이 보고서를 구매해야 하는 이유:

• 약물 종류, 투여 경로, 기술, 유통 채널 및 지역별 전 세계 동형접합성 가족성 고콜레스테롤혈증 시장 세분화를 시각화하고 주요 상업적 자산과 기업을 파악하기 위함입니다.

• 트렌드 분석 및 공동 개발을 통해 상업적 기회를 파악합니다.

• 모든 세그먼트를 포함한 동형접합성 가족성 고콜레스테롤혈증 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트가 제공됩니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석이 담긴 PDF 보고서가 제공됩니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑이 엑셀 파일로 제공됩니다.

글로벌 동형접합성 가족성 고콜레스테롤혈증 시장 보고서는 약 53개의 표, 54개의 그림, 195페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Homozygous Familial Hypercholesterolemia Market reached US$ 83.7 million in 2022 and is expected to reach US$ 101.8 million by 2030 growing with a CAGR of 2.5% during the forecast period 2023-2030. The trend such as the shift towards advancements in genetic diagnostics due to its precise potential in identification of genetic mutations responsible for HoFH, facilitating early diagnosis is expected to dominate the global homozygous familial hypercholesterolemia market.
The global homozygous familial hypercholesterolemia market has grown significantly in recent years and is projected to continue on its upward trend. The market is undergoing a transformational period, influenced by several significant trends such development of novel technologies like CRISPR-Cas9 and RNA interference (RNAi).
Furthermore, the rising prevalence of cardiovascular disorders, launch of potential emerging therapies such as monoclonal antibodies, rising awareness of the disease, increasing number of clinical trials are driving up the homozygous familial hypercholesterolemia market size.
The growing research activities for treating disease using homozygous familial hypercholesterolemia approach and presence of establish biopharmaceutical and pharmaceutical companies are some of the factors in demand from North American regions. With significant competitors like AstraZeneca, Viatris Inc., Accord Healthcare, and others actively operating in the market.
Dynamics
The Increasing Prevalence of Cardiovascular Disease to Drive the Growth of the Homozygous familial hypercholesterolemia Market
The rising prevalence of cardiovascular diseases (CVDs) is a major driver for the homozygous familial hypercholesterolemia (HoFH) market. As HoFH is characterized by high levels of LDL-C and increased risk of CVDs like heart attacks and strokes, growing awareness of this disease fuels early detection and interventions that in turn drive demand for efficient HoFH treatments.
For instance, according to Centers for Disease Control and Prevention 2023 report, heart disease disease is one of the leading cause of death in U.S. Every 40 seconds some or other person in U.S. suffer from heart attack. In U.S. every year, approximately 805,000 people have heart attack. Moreover coronary heart disease is the most common type of heart disease, killing 375,476 people in 2021. As the CVD and coronary heart disease burden continues to increase, the HoFH market is expected to grow during the forecast period.
The Growing Advancements in Gene Therapies will Drive the Homozygous Familial Hypercholesterolemia Market Growth
The growing technological advancement in homozygous familial hypercholesterolemia such as CRISPR-Cas9, small interfering RNA (SiRNA), exosome-mediated therapy and others is expected to drive the demand for the market. The CRISPR/Cas9 system is revolutionary third generation gene editing tool after ZFNs and TALENs and currently the genome editing tool of choice.
For instance, according to National Library of Medicine 2022 article state that, the adeno-associated virus (AAV) containing the CRISPR/Cas9 gene editing system (AAV-CRISPR/Cas9) was used in a recent in vivo animal study to target LDLR mutant mice with impaired LDL receptor function (AAV-CRISPR/Cas9). The researchers discovered that using AAV-CRISPR/Cas9 gene editing, they were able to partially fix the mutation in hepatocytes, restoring LDL receptor protein expression.
This resulted in major decreases in serum total cholesterol, triglyceride, and LDL cholesterol levels. As a result, atherosclerotic plaque formation in the aorta reduced significantly, indicating CRISPR/Cas9's potential promise for treating heterozygous and homozygous familial hypercholesterolemia. Thus, advancements in technologies for gene therapies will drive the demand for the market over the forecast period.
The High Cost Associated with the Homozygous Familial Hypercholesterolemia Treatment Will Hamper the Growth of the Market
The high cost of treatment for homozygous familial hypercholesterolemia is a significant barrier for this market. The high costs of these medications may make them difficult to afford for patients, preventing many people from obtaining these vital therapies. This financial burden can affect more persons in low-income areas, causing gaps in who can receive therapies that can save lives for patients with HoFH.
For instance, Lomitapide drug, sold under the brand of Juxtapid in U.S for reducing the low-density lipoprotein (LDL) apheresis cost around cost around. This oral 5 mg capsule cost around $53,471 for a supply of 28 capsules. Moreover, unavailability of generic version may find it difficult to afford for the pateint in developing and low income countries. Thus, owing to the above factors the market is expected to face a restraint over the foreseeable future.
Segment Analysis
The global homozygous familial hypercholesterolemia market is segmented based on drug class, route of administration, technology, distribution channel, and region.
Owing to the Better Effectiveness, the Statins Segment Accounted for Approximately 47.6% of the Homozygous Familial Hypercholesterolemia Market Share
The statins segment is poised to dominate the homozygous familial hypercholesterolemia market due to effectiveness in reducing LDL cholesterol levels and managing cardiovascular risk. Statins are the mainstay treatment for treating the homozygous familial hypercholesterolemia due to its ability to reduce the LDL-C by diminishing hepatic cholesterol synthesis acting on the 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA)-reductase.
Also, the rising prevalence of atherosclerosis is major factors where treatment such as statins are very effective. For instance, according to Family Heart Foundation studies, it has shown that statins can reduce LDL-cholesterol by 35 to 55% and can reduce the risk of cardiovascular disease by 22% for each 40 mg/dL reduction in LDL-cholesterol.
Currently, rosuvastatin has the most potent lipid-lowering capability of any presently available statin and is suggested for people with primary hyperlipidemia and mixed dyslipidemia, homozygous FH, primary dysbetalipoproteinemia, and hypertriglyceridemia. Also, statins are ery effective in children and are proven to be safe with children suffering from lipid disorders.
Moreover, statins are more effective when given in combination with other adjuncts treatment such as evinacumab, PCSK9 inhibitors, and other. Many new treatment are that are use as adjuncts to statins are expected to get FDA approval. Thus, due to statins better effectiveness the segment is expected to dominate over the forecast period.
Geographical Penetration
North America Accounted for Approximately 41.7% of the Market Share in 2022, Owing to the Rising Prevalence of Atherosclerotic Cardiovascular Disease (ASCVD)
North America, particularly the U.S., dominates the global homozygous familial hypercholesterolemia market due to presence of huge number of key players settled in the region, growing prevalence of atherosclerotic cardiovascular disease (ASCVD), and high research activities along with developments of technologies by major organization in the region.
For instance, according to National Librabry of Medicine 2022 article, approximately the prevalence of ASCVD in the US was about 24 million in 2019, approximately 10% of the total US population are above 21 years old. It was found heavy comorbidity burden among ASCVD patients and 31.2% were at very high risk for recurrent events. Thus, owing to above factors the region is expected to grow over the forecast period.
Competitive Landscape
The major global players in the homozygous familial hypercholesterolemia market include AstraZeneca, Viatris Inc., Teva Pharmaceutical Industries Ltd., Accord Healthcare, Changzhou Pharmaceutical Factory, Regeneron Pharmaceuticals, Inc., Amryt Pharma plc, Amgen Inc., Organon, Global Inc., CMP Pharma, and among others.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the lifestyle and management of people with FH, especially homozygous FH (HoFH). Fear of COVID-19 has caused many to avoid getting medical attention. Furthermore, because FH patients were designated high-risk groups due to their greater vulnerability to COVID-19 infection, FH patients' access to cardiovascular therapy and prevention during the pandemic was limited.
For intance, according to the National Librabry of Medicine 2022 article, this population-based study found that FH patients with COVID-19 have a considerably increased risk of acute myocardial infarction. Overall, the COVID-19 pandemic has established hurdles to cardiovascular therapy for patients with FH, particularly HoFH. Thereby creating a major impact on the homozygous familial hypercholesterolemia market.
By Drug Class
• Statins
• Cholesterol Absorption Inhibitors
• PCSK9 Inhibitors
• MTP Inhibitors
• ANGPTL3 Inhibitors
By Route of Administration
• Oral
• Parenteral
• Nasal
By Technology
• CRISPR-Cas9
• RNA Interference
• Nanoparticle-Based Therapies
By Distribution Channel
• Hospitals
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• On March 22, 2023, Regeneron Pharmaceuticals, Inc. announced that the FDA has extended the approval of Evkeeza (evinacumab-dgnb) as an addition to other lipid-lowering medicines in children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH). Evkeeza is the first angiopoietin-like 3 (ANGPTL3) inhibitor medication approved for children as young as 5 years old to decrease dangerously high levels of low-density lipoprotein cholesterol (LDL-C) caused by HoFH.
• On April 1, 2021, The FDA has approved Praluent (alirocumab) injectable for adult patients with homozygous familial hypercholesterolemia (HoFH), a hereditary disease that causes significantly elevated cholesterol. Praluent is not intended to be taken alone, but rather to be combined with other HoFH therapies.
DMI Opinion
The Global Homozygous Familial Hypercholesterolemia (HoFH) Market is expected to rise rapidly, because of advances in genetic diagnostics, gene treatments such as CRISPR-Cas9, and growing awareness of the condition. The link between HoFH and cardiovascular disorders creates demand for effective treatments, but addressing treatment affordability and accessibility is essential. While gene editing technologies have immense possibilities, but don't come without problems and safety issues.
The market is segmented based on several characteristics, with North America dominant due to research capability and disease incidence. New treatments such as Evkeeza and Praluent demonstrate continued innovation, whereas COVID-19 highlights the importance of robust healthcare systems and equal access to therapy. Balancing developments with ethical issues remain crucial in navigating this landscape.
Why Purchase the Report?
• To visualize the global homozygous familial hypercholesterolemia market segmentation based on drug class, route of administration, technology, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of homozygous familial hypercholesterolemia market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.
The global homozygous familial hypercholesterolemia market report would provide approximately 53 tables, 54 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Route of Administration
3.3. Snippet by Technology
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The Increasing Prevalence of Cardiovascular Disease
4.1.1.2. The Growing Advancements in Gene Therapies
4.1.2. Restraints
4.1.2.1. The High Cost Associated with the Homozygous Familial Hypercholesterolemia Treatment
4.1.3. Opportunity
4.1.3.1. Increasing Demand for Personalized Medicine
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Statins*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Cholesterol Absorption Inhibitors
7.4. PCSK9 Inhibitors
7.5. MTP Inhibitors
7.6. ANGPTL3 Inhibitors
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Parenteral
8.4. Nasal
9. By Technology
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.1.2. Market Attractiveness Index, By Technology
9.2. CRISPR-Cas9*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. RNA Interference
9.4. Nanoparticle-Based Therapies
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Spain
11.3.7.5. Italy
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. AstraZeneca*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Viatris Inc.
13.3. Teva Pharmaceutical Industries Ltd.
13.4. Accord Healthcare
13.5. Changzhou Pharmaceutical Factory
13.6. Regeneron Pharmaceuticals, Inc.
13.7. Amryt Pharma plc
13.8. Amgen Inc.
13.9. Organon Global Inc.
13.10. CMP Pharma
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

AstraZeneca, 4.	Key Developments, Viatris Inc., Teva Pharmaceutical Industries Ltd., Accord Healthcare, Changzhou Pharmaceutical Factory, Regeneron Pharmaceuticals, Inc., Amryt Pharma plc, Amgen Inc., Organon Global Inc., CMP Pharma

표 목록 (Tables)

List of Tables

Table 1 Global Homozygous Familial Hypercholesterolemia Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Homozygous Familial Hypercholesterolemia Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Homozygous Familial Hypercholesterolemia Market Value, By Technology, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Homozygous Familial Hypercholesterolemia Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Homozygous Familial Hypercholesterolemia Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Homozygous Familial Hypercholesterolemia Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Million)

Table 7 Global Homozygous Familial Hypercholesterolemia Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 8 Global Homozygous Familial Hypercholesterolemia Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 9 Global Homozygous Familial Hypercholesterolemia Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 10 Global Homozygous Familial Hypercholesterolemia Market Value, By Technology, 2022, 2026 & 2030 (US$ Million)

Table 11 Global Homozygous Familial Hypercholesterolemia Market Value, By Technology, 2021-2030 (US$ Million)

Table 12 Global Homozygous Familial Hypercholesterolemia Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 13 Global Homozygous Familial Hypercholesterolemia Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 14 Global Homozygous Familial Hypercholesterolemia Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 15 Global Homozygous Familial Hypercholesterolemia Market Value, By Region, 2021-2030 (US$ Million)

Table 16 North America Homozygous Familial Hypercholesterolemia Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 17 North America Homozygous Familial Hypercholesterolemia Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 18 North America Homozygous Familial Hypercholesterolemia Market Value, By Technology, 2021-2030 (US$ Million)

Table 19 North America Homozygous Familial Hypercholesterolemia Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 North America Homozygous Familial Hypercholesterolemia Market Value, By Country, 2021-2030 (US$ Million)

Table 21 South America Homozygous Familial Hypercholesterolemia Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 22 South America Homozygous Familial Hypercholesterolemia Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 23 South America Homozygous Familial Hypercholesterolemia Market Value, By Technology, 2021-2030 (US$ Million)

Table 24 South America Homozygous Familial Hypercholesterolemia Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 25 South America Homozygous Familial Hypercholesterolemia Market Value, By Country, 2021-2030 (US$ Million)

Table 26 Europe Homozygous Familial Hypercholesterolemia Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 27 Europe Homozygous Familial Hypercholesterolemia Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 28 Europe Homozygous Familial Hypercholesterolemia Market Value, By Technology, 2021-2030 (US$ Million)

Table 29 Europe Homozygous Familial Hypercholesterolemia Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 30 Europe Homozygous Familial Hypercholesterolemia Market Value, By Country, 2021-2030 (US$ Million)

Table 31 Asia-Pacific Homozygous Familial Hypercholesterolemia Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 32 Asia-Pacific Homozygous Familial Hypercholesterolemia Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 33 Asia-Pacific Homozygous Familial Hypercholesterolemia Market Value, By Technology, 2021-2030 (US$ Million)

Table 34 Asia-Pacific Homozygous Familial Hypercholesterolemia Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 35 Asia-Pacific Homozygous Familial Hypercholesterolemia Market Value, By Country, 2021-2030 (US$ Million)

Table 36 Middle East & Africa Homozygous Familial Hypercholesterolemia Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 37 Middle East & Africa Homozygous Familial Hypercholesterolemia Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 38 Middle East & Africa Homozygous Familial Hypercholesterolemia Market Value, By Technology, 2021-2030 (US$ Million)

Table 39 Middle East & Africa Homozygous Familial Hypercholesterolemia Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 40 AstraZeneca: Overview

Table 41 AstraZeneca: Product Portfolio

Table 42 AstraZeneca: Key Developments

Table 43 Viatris Inc.: Overview

Table 44 Viatris Inc.: Product Portfolio

Table 45 Viatris Inc.: Key Developments

Table 46 Teva Pharmaceutical Industries Ltd.: Overview

Table 47 Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 48 Teva Pharmaceutical Industries Ltd.: Key Developments

Table 49 Accord Healthcare: Overview

Table 50 Accord Healthcare: Product Portfolio

Table 51 Accord Healthcare: Key Developments

Table 52 Changzhou Pharmaceutical Factory: Overview

Table 53 Changzhou Pharmaceutical Factory: Product Portfolio

Table 54 Changzhou Pharmaceutical Factory: Key Developments

Table 55 Regeneron Pharmaceuticals, Inc.: Overview

Table 56 Regeneron Pharmaceuticals, Inc.: Product Portfolio

Table 57 Regeneron Pharmaceuticals, Inc.: Key Developments

Table 58 Amryt Pharma plc: Overview

Table 59 Amryt Pharma plc: Product Portfolio

Table 60 Amryt Pharma plc: Key Developments

Table 61 Amgen Inc.: Overview

Table 62 Amgen Inc.: Product Portfolio

Table 63 Amgen Inc.: Key Developments

Table 64 Organon Global Inc.: Overview

Table 65 Organon Global Inc.: Product Portfolio

Table 66 Organon Global Inc.: Key Developments

Table 67 CMP Pharma: Overview

Table 68 CMP Pharma: Product Portfolio

Table 69 CMP Pharma: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 2 Global Homozygous Familial Hypercholesterolemia Market Share, By Drug Class, 2022 & 2030 (%)

Figure 3 Global Homozygous Familial Hypercholesterolemia Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 4 Global Homozygous Familial Hypercholesterolemia Market Share, By Technology, 2022 & 2030 (%)

Figure 5 Global Homozygous Familial Hypercholesterolemia Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 6 Global Homozygous Familial Hypercholesterolemia Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Homozygous Familial Hypercholesterolemia Market Y-o-Y Growth, By Drug Class, 2022-2030 (%)

Figure 8 Statins Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 9 Cholesterol Absorption Inhibitors Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 10 PCSK9 Inhibitors Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 11 MTP Inhibitors Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 12 ANGPTL3 Inhibitors Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 13 Global Homozygous Familial Hypercholesterolemia Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 14 Oral Route of Administration in Global Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 15 Parenteral Route of Administration in Global Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 16 Nasal Route of Administration in Global Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 17 Global Homozygous Familial Hypercholesterolemia Market Y-o-Y Growth, By Technology, 2022-2030 (%)

Figure 18 CRISPR-Cas9 Technology in Global Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 19 RNA Interference Technology in Global Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 20 Nanoparticle-Based Therapies Technology in Global Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 21 Global Homozygous Familial Hypercholesterolemia Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 22 Hospitals Distribution Channel in Global Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 23 Retail Pharmacies Distribution Channel in Global Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 24 Online Pharmacies Distribution Channel in Global Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 25 Global Homozygous Familial Hypercholesterolemia Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 26 North America Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 27 Asia-Pacific Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 28 Europe Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 29 South America Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 30 Middle East and Africa Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 31 North America Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 32 North America Homozygous Familial Hypercholesterolemia Market Share, By Drug Class, 2022 & 2030 (%)

Figure 33 North America Homozygous Familial Hypercholesterolemia Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 34 North America Homozygous Familial Hypercholesterolemia Market Share, By Technology, 2022 & 2030 (%)

Figure 35 North America Homozygous Familial Hypercholesterolemia Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 36 North America Homozygous Familial Hypercholesterolemia Market Share, By Country, 2022 & 2030 (%)

Figure 37 South America Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 38 South America Homozygous Familial Hypercholesterolemia Market Share, By Drug Class, 2022 & 2030 (%)

Figure 39 South America Homozygous Familial Hypercholesterolemia Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 40 South America Homozygous Familial Hypercholesterolemia Market Share, By Technology, 2022 & 2030 (%)

Figure 41 South America Homozygous Familial Hypercholesterolemia Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 42 South America Homozygous Familial Hypercholesterolemia Market Share, By Country, 2022 & 2030 (%)

Figure 43 Europe Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 44 Europe Homozygous Familial Hypercholesterolemia Market Share, By Drug Class, 2022 & 2030 (%)

Figure 45 Europe Homozygous Familial Hypercholesterolemia Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 46 Europe Homozygous Familial Hypercholesterolemia Market Share, By Technology, 2022 & 2030 (%)

Figure 47 Europe Homozygous Familial Hypercholesterolemia Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 48 Europe Homozygous Familial Hypercholesterolemia Market Share, By Country, 2022 & 2030 (%)

Figure 49 Asia-Pacific Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 50 Asia-Pacific Homozygous Familial Hypercholesterolemia Market Share, By Drug Class, 2022 & 2030 (%)

Figure 51 Asia-Pacific Homozygous Familial Hypercholesterolemia Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 52 Asia-Pacific Homozygous Familial Hypercholesterolemia Market Share, By Technology, 2022 & 2030 (%)

Figure 53 Asia-Pacific Homozygous Familial Hypercholesterolemia Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 54 Asia-Pacific Homozygous Familial Hypercholesterolemia Market Share, By Country, 2022 & 2030 (%)

Figure 55 Middle East & Africa Homozygous Familial Hypercholesterolemia Market Value, 2021-2030 (US$ Million)

Figure 56 Middle East & Africa Homozygous Familial Hypercholesterolemia Market Share, By Drug Class, 2022 & 2030 (%)

Figure 57 Middle East & Africa Homozygous Familial Hypercholesterolemia Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 58 Middle East & Africa Homozygous Familial Hypercholesterolemia Market Share, By Technology, 2022 & 2030 (%)

Figure 59 Middle East & Africa Homozygous Familial Hypercholesterolemia Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 60 AstraZeneca: Financials

Figure 61 Viatris Inc.: Financials

Figure 62 Teva Pharmaceutical Industries Ltd.: Financials

Figure 63 Accord Healthcare: Financials

Figure 64 Changzhou Pharmaceutical Factory: Financials

Figure 65 Regeneron Pharmaceuticals, Inc.: Financials

Figure 66 Amryt Pharma plc: Financials

Figure 67 Amgen Inc.: Financials

Figure 68 Organon Global Inc.: Financials

Figure 69 CMP Pharma: Financials

글로벌 동형접합성 가족성 고콜레스테롤혈증 시장 – 2023-2030

Global Homozygous Familial Hypercholesterolemia Market - 2023-2030